Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy
Pharma
Roche's Vabysmo will rise above Eylea biosim threat, exec says
While Vabysmo and Ocrevus are Roche's largest assets, the biggest surprise in the company's Q3 came from Elevidys, the DMD gene therapy from Sarepta.
Angus Liu
Oct 23, 2024 11:24am
Pfizer lays off 75 more workers in NC in wake of DMD trial fail
Oct 22, 2024 5:28pm
Sanofi sues Sarepta over 2 gene therapy manufacturing patents
Jul 30, 2024 5:21pm
Pfizer's DMD loss is Sarepta's gain: analysts
Jun 13, 2024 10:58am
NS Pharma's Duchenne drug Viltepso flunks confirmatory trial
May 28, 2024 11:54am
Sarepta's Elevidys off to strong start despite label restriction
Nov 2, 2023 4:21pm
